Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

被引:140
作者
Trotter, CL [1 ]
Gay, NJ [1 ]
Edmunds, WJ [1 ]
机构
[1] Hlth Protect Agcy, Ctr Infect, Modelling & Econ Unit, London NW9 5EQ, England
关键词
disease transmission; immunity; herd; meningitis; meningococcal; serogroup C; meningococcal vaccines; models; theoretical; vaccination; vaccines; conjugate;
D O I
10.1093/aje/kwi160
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Much interest has surrounded the use of conjugate vaccines in recent years, with the development of vaccines against disease caused by Haemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae. These vaccines offer the potential for safe and effective disease control, but some questions remain, particularly regarding the duration and mechanisms of protection and the longer-term impact of vaccination on carriage. In this paper, the authors use data on immunization with serogroup C meningococcal conjugate vaccines in England and Wales to develop and apply a mathematical model to investigate the direct and indirect (herd immunity) effects of a conjugate vaccine program. A realistic, age-structured, dynamic model was developed and parameterized and was fitted to epidemiologic data from England and Wales. The effects of a range of vaccine strategies, including hypothetical scenarios, were investigated. The basic reproduction number was estimated to be 1.36. Catch-up vaccination targeting teenagers generated substantial herd immunity and was important in controlling disease rapidly. The results were sensitive to changes in the assumptions regarding the method of vaccine action, particularly duration of protection and efficacy of vaccination against carriage acquisition. This model can be used to help predict the potential impact of vaccine strategies both in the United Kingdom and elsewhere.
引用
收藏
页码:89 / 100
页数:12
相关论文
共 30 条
[21]   Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end [J].
Lansley, M ;
Bedford, H .
VACCINE, 2003, 21 (21-22) :2877-2881
[22]   Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination [J].
Maiden, MCJ ;
Stuart, JM .
LANCET, 2002, 359 (9320) :1829-1830
[23]   Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis [J].
Ramsay, ME ;
Andrews, NJ ;
Trotter, CL ;
Kaczmarski, EB ;
Miller, E .
BRITISH MEDICAL JOURNAL, 2003, 326 (7385) :365-366
[24]   Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England [J].
Ramsay, ME ;
Andrews, N ;
Kaczmarski, EB ;
Miller, E .
LANCET, 2001, 357 (9251) :195-196
[25]  
Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169
[26]  
Trotter C L, 2003, Commun Dis Public Health, V6, P55
[27]  
Trotter C L, 2002, Commun Dis Public Health, V5, P220
[28]   Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction [J].
Trotter, CL ;
Andrews, NJ ;
Kaczmarski, EB ;
Miller, E ;
Ramsay, ME .
LANCET, 2004, 364 (9431) :365-367
[29]  
TROTTER CL, IN PRESS EPIDEMIOL I
[30]  
2003, NZ PUBLIC HLTH REP, V6, P57